ANDA 203907, held by Sciegen Pharms. Donepezil Hydrochloride.
As of Nov 16, 2026, ANDA 203907 (Donepezil Hydrochloride), held by Sciegen Pharms, was first approved by FDA on Oct 29, 2014, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 29, 2014 | Original application | Approved | None posted |
| Donepezil Hydrochloride5MG · tablet;oral | Donepezil Hydrochloride | Rx |
| Donepezil Hydrochloride10MG · tablet;oral | Donepezil Hydrochloride | Rx |
| Aug 11, 2020 | Supplement 12Labeling · Standard review | Approved | None posted |
| Dec 1, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 29, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters